Clinical Trial Detail

NCT ID NCT03263936
Title Epigenetic Reprogramming in Relapse/Refractory AML
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Therapeutic Advances in Childhood Leukemia Consortium
Indications

acute myeloid leukemia

Therapies

Vorinostat

Decitabine

Cytarabine

Fludarabine

Filgrastim

Age Groups: adult child

No variant requirements are available.